NEUP Quote, Financials, Valuation and Earnings

Adverum Biotechnologies, Inc. has a net margin of 75.08% compared to Neuphoria Therapeutics, Inc.'s net margin of -2713.4%. Neuphoria Therapeutics, Inc.'s return on equity of -8.02% beat Adverum Biotechnologies, Inc.'s return on equity of -558.69%.

Neuphoria Therapeutics, Inc. has a consensus price target of $9.77, signalling upside risk potential of 151.07%. On the other hand Adverum Biotechnologies, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 14.68%. Given that Neuphoria Therapeutics, Inc. has higher upside potential than Adverum Biotechnologies, Inc., analysts believe Neuphoria Therapeutics, Inc. is more attractive than Adverum Biotechnologies, Inc..

Neuphoria Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adverum Biotechnologies, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.055%.

Neuphoria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adverum Biotechnologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuphoria Therapeutics, Inc. pays -- of its earnings as a dividend. Adverum Biotechnologies, Inc. pays out -- of its earnings as a dividend.

Neuphoria Therapeutics, Inc. quarterly revenues are --, which are smaller than Adverum Biotechnologies, Inc. quarterly revenues of --. Neuphoria Therapeutics, Inc.'s net income of -$9.9M is higher than Adverum Biotechnologies, Inc.'s net income of -$47.7M. Notably, Neuphoria Therapeutics, Inc.'s price-to-earnings ratio is 4.31x while Adverum Biotechnologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuphoria Therapeutics, Inc. is 14.87x versus 89.16x for Adverum Biotechnologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inhibrx Biosciences, Inc. has a net margin of 75.08% compared to Neuphoria Therapeutics, Inc.'s net margin of -2204.15%. Neuphoria Therapeutics, Inc.'s return on equity of -8.02% beat Inhibrx Biosciences, Inc.'s return on equity of -151.49%.

Neuphoria Therapeutics, Inc. has a consensus price target of $9.77, signalling upside risk potential of 151.07%. On the other hand Inhibrx Biosciences, Inc. has an analysts' consensus of $12.00 which suggests that it could fall by -86.07%. Given that Neuphoria Therapeutics, Inc. has higher upside potential than Inhibrx Biosciences, Inc., analysts believe Neuphoria Therapeutics, Inc. is more attractive than Inhibrx Biosciences, Inc..

Neuphoria Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inhibrx Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Neuphoria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inhibrx Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuphoria Therapeutics, Inc. pays -- of its earnings as a dividend. Inhibrx Biosciences, Inc. pays out -- of its earnings as a dividend.

Neuphoria Therapeutics, Inc. quarterly revenues are --, which are smaller than Inhibrx Biosciences, Inc. quarterly revenues of --. Neuphoria Therapeutics, Inc.'s net income of -$9.9M is higher than Inhibrx Biosciences, Inc.'s net income of -$35.3M. Notably, Neuphoria Therapeutics, Inc.'s price-to-earnings ratio is 4.31x while Inhibrx Biosciences, Inc.'s PE ratio is 0.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuphoria Therapeutics, Inc. is 14.87x versus 936.51x for Inhibrx Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 75.08% compared to Neuphoria Therapeutics, Inc.'s net margin of -3135.32%. Neuphoria Therapeutics, Inc.'s return on equity of -8.02% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Neuphoria Therapeutics, Inc. has a consensus price target of $9.77, signalling upside risk potential of 151.07%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 64.32%. Given that Neuphoria Therapeutics, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Neuphoria Therapeutics, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Neuphoria Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Neuphoria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuphoria Therapeutics, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Neuphoria Therapeutics, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Neuphoria Therapeutics, Inc.'s net income of -$9.9M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Neuphoria Therapeutics, Inc.'s price-to-earnings ratio is 4.31x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuphoria Therapeutics, Inc. is 14.87x versus 39.08x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

X4 Pharmaceuticals, Inc. has a net margin of 75.08% compared to Neuphoria Therapeutics, Inc.'s net margin of -1689.24%. Neuphoria Therapeutics, Inc.'s return on equity of -8.02% beat X4 Pharmaceuticals, Inc.'s return on equity of -279.19%.

Neuphoria Therapeutics, Inc. has a consensus price target of $9.77, signalling upside risk potential of 151.07%. On the other hand X4 Pharmaceuticals, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 122.22%. Given that Neuphoria Therapeutics, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Neuphoria Therapeutics, Inc. is more attractive than X4 Pharmaceuticals, Inc..

Neuphoria Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison X4 Pharmaceuticals, Inc. has a beta of 0.421, suggesting its less volatile than the S&P 500 by 57.861%.

Neuphoria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. X4 Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuphoria Therapeutics, Inc. pays -- of its earnings as a dividend. X4 Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Neuphoria Therapeutics, Inc. quarterly revenues are --, which are smaller than X4 Pharmaceuticals, Inc. quarterly revenues of $1.8M. Neuphoria Therapeutics, Inc.'s net income of -$9.9M is higher than X4 Pharmaceuticals, Inc.'s net income of -$29.8M. Notably, Neuphoria Therapeutics, Inc.'s price-to-earnings ratio is 4.31x while X4 Pharmaceuticals, Inc.'s PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuphoria Therapeutics, Inc. is 14.87x versus 1.70x for X4 Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.